Home News

News

Daiichi Sankyo Submits New Drug Application for Trastuzumab Deruxtecan to Japanese Regulators

Earlier this week Daiichi Sankyo confirmed this week that it has submitted a New Drug Application (NDA)...
Justin Sweeley, Novasep

Webinar: When to Apply Design of Experiments (DoE) to ADC Development

Live Webinar: When to Apply Design of Experiments (DoE) to ADC Development Date: September 24, 2019 Time: 8AM PDT / 5PM...

Anti-VEGF antibody biopolymer conjugate KSI-301 in Treatment of Retinal Vascular Diseases Shows Encouraging Results...

This weekend results from novel therapeutics to treat chronic, high-prevalence retinal diseases, were presented during the European...

FDA Clears IND Application for Phase I/II Study of OBI-999 in Epithelial Cancer

Earlier this week the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application...

Strategic Alliance Helps the Development Antibody Fragment-Drug Conjugates

In August 2019 Antikor Biopharma and Essex Bio-Technology confirmed that the companies had entered into an investment...
Featured Image: Nyhavn, Copenhagen, Denmark. Courtesy: © Fotolia. Used with permission.

ADCendo Secures Funding to Fill Gap After Market Withdrawal of Olaratumab in STS

ADCendo, a biotechnology spin-out from the University of Copenhagen and the Finsen Laboratory of Rigshospitalet in Copenhagen, Denmark, developing...

5 Things in ADCs This Week – August 30, 2019

Hello all,It’s been almost three weeks since my last update which means that there is a massive amount of...

AbbVie Discontinues Research and Development Program for Rovalpituzumab Tesirine

MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced...
Journal Articles - Paper and Labptop

Enabling Heterobifunctional, Dual “Click,” Antibody Modification via Microbial Transglutaminase

With 5 approved and commercially available antibody-drug conjugates, this class of therapeutics, combining the efficacy of small-molecule therapeutics with...
Featured Image: Journal + glasses. Courtesy: © 2017 - 2019. Fotolia. Used with permission.

Identifying Regulators of Antibody–drug Conjugate Toxicity

Antibody–drug conjugates or ADCs selectively deliver a a cytotoxic payload to target cancer cells, making them important anti-cancer therapeutics....

FEATURED RESOURCES